The Asia Corner - From the Editors of PharmAsia News May 26, 2009
In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan, and the Pacific Rim.
Read today's features...
Continue reading "The Asia Corner - From the Editors of PharmAsia News" »
The Health Care Reform Corner – From the editors of "The Pink Sheet" May 26, 2009
What are policymakers and stakeholders in Washington saying and doing about health care reform? In this periodic BioPharma Today feature, the editors of"The Pink Sheet" and "The Pink Sheet" DAILY highlight some of the major developments chronicled in those publications.
Read today's feature...
Continue reading "The Health Care Reform Corner – From the editors of "The Pink Sheet" " »
Article Reprinted from "The Pink Sheet" May 26, 2009
FDA's aggressive enforcement of its advertising standards, and the agency's new enforcement allies, mean that industry may now have more to fear from a citation letter.
"We applaud the new aggressiveness by DDMAC, and as a result, we have more opportunities for synergies working with the federal government," Oregon Assistant Attorney General David Hart said during a May 20 webinar sponsored by Elsevier Business Intelligence. Read on...
Continue reading "FDA Ad Enforcement Steams On; Are “Days Of Pushing The Envelope” Over? " »
Article preview from "The Pink Sheet" DAILY May 26, 2009
ATLANTA - Patient power is driving disease foundations to invest more money in turning discoveries into therapies at a time when biotechs sorely need the cash. In turn, the struggling companies are getting more than financial support in the bargain. Read on...
Continue reading "Venture Philanthropy Reaches Out To Biotechs " »
Article preview from The RPM Report May 26, 2009
For FDA's top biologics review manager, Jesse Goodman, the announcement of the membership list of the Federal Coordinating Committee on Comparative Effectiveness Research was also his debut in a new role: acting chief medical officer. His background in infectious diseases and preparedness aligns well with the topside leadership in FDA and HHS. Read more...
Continue reading "FDA's Jesse Goodman is Rising Star Within Agency" »
Full article reprinted from Start-Up May 26, 2009
University College London spin-out Pentraxin's February 2009 tie-up with GlaxoSmithKline in amyloidosis showed GSK's willingness to invest in risky, early-stage research. Weeks later, Pentraxin announced promising clinical data with a related program in Alzheimer's, raising the possibility that this alliance may yet expand beyond a specialist niche. Read more...
Continue reading "GSK/Pentraxin: Targeting SAP in Amyloidosis, and Maybe Alzheimer's Too" »
The Health Care Reform Corner – From the editors of "The Pink Sheet" May 19, 2009
What are policymakers and stakeholders in Washington saying and doing about health care reform? In this periodic BioPharma Today feature, the editors of"The Pink Sheet" and "The Pink Sheet" DAILY highlight some of the major developments chronicled in those publications.
Read today's features...
Continue reading "The Health Care Reform Corner – From the editors of "The Pink Sheet" " »
Article reprinted from The RPM Report May 19, 2009
Biosimilars haven’t had a huge impact in Europe—yet. Sponsors and analysts expect that to change over time. Will the US market parallel the European experience? Read on...
Continue reading "European Biosimilars’ Market Performance Mirrors US Legislative Progress: Slow but Steady " »
The Asia Corner - From the Editors of PharmAsia News May 19, 2009
In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan, and the Pacific Rim.
Read today's features...
Continue reading "The Asia Corner - From the Editors of PharmAsia News" »
Article Reprinted from "The Pink Sheet" May 19, 2009
Independent pharmacies are hoping the Federal Trade Commission's post-merger investigation of Merck's acquisition of Medco can serve as a model for their requested investigation into the merger between CVS and Caremark. Read more now...
Continue reading "NCPA Seeks FTC Investigation Of CVS Caremark, With Merck-Medco As Model " »